Pladienolide B
(Synonyms: 普拉地内酯B) 目录号 : GC18780An inhibitor of splicing factor SF3b
Cas No.:445493-23-2
Sample solution is provided at 25 µL, 10mM.
Spliceosomes mediate the processing of pre-mRNA into mature mRNA.[1],[2] Each spliceosome is a multiunit complex containing several proteins and RNA molecules that work in unison to repeatedly cleave and rejoin segments of mRNA.[1],[3] Pladienolide B is a macrocyclic lactone that selectively binds splicing factor 3b and inhibits mRNA splicing.[4],[5] Through this action, pladienolide B potently blocks the growth of proliferating cells with mean IC50 values of 1.6 nM for six gastric cancer cell lines.[6],[7] In xenograft tumors generated in mice using human cancer cells, pladienolide B blocks mRNA splicing and induces apoptosis, clearing tumors within two weeks after treatment.[7]
剪接体介导 pre-mRNA 加工成成熟 mRNA。[1]、[2] 每个剪接体都是一个多单元复合体,包含多个蛋白质和 RNA 分子,它们协同工作以反复切割和重新连接 mRNA 片段。 [1]、[3] Pladienolide B 是一种大环内酯,可选择性结合剪接因子 3b 并抑制 mRNA 剪接。[4]、[5] 通过这种作用,pladienolide B 有效地阻止增殖细胞的生长,平均 IC50 值为 1.6 nM 对六种胃癌细胞系。[6],[7] 在使用人类癌细胞的小鼠体内产生的异种移植肿瘤中,pladienolide B 阻断 mRNA 剪接并诱导细胞凋亡,在治疗后两周内清除肿瘤。[7]
Reference:
[1]. Naro, C., and Sette, C. Phosphorylation-mediated regulation of alternative splicing in cancer. Int.J.Cell Biol. 2013, 1-16 (2013).
[2]. Webb, T.R., Joyner, A.S., and Potter, P.M. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discovery Today 18(1-2), 43-49 (2013).
[4]. Yokoi, A., Kotake, Y., Takahashi, K., et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS Journal 278(24), 4870-4880 (2011).
[5]. Kotake, Y., Sagane, K., Owa, T., et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nature Chemical Biology 3, 570-575 (2007).
[6]. Effenberger, K.A., Anderson, D.D., Bray, W.M., et al. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs. The Journal of Biological Chemisty 289, 1938-1947 (2014).
[7]. Sato, M., Muguruma, N., Nakagawa, T., et al. High antitumor activity of pladienolide B and its derivative in gastric cancer. Cancer Science 105(1), 110-116 (2014).
Cas No. | 445493-23-2 | SDF | |
别名 | 普拉地内酯B | ||
化学名 | (4R,7R,8S,9E,11S,12S)-8-(acetyloxy)-4,7-dihydroxy-12-[(1E,3E,5S)-6-[(2R,3R)-3-[(1R,2S)-2-hydroxy-1-methylbutyl]-2-oxiranyl]-1,5-dimethyl-1,3-oxacyclododec-9-en-2-one | ||
Canonical SMILES | O[C@H]1CC(O[C@H](/C(C)=C/C=C/[C@@H](C)C[C@@H]2[C@]([C@H](C)[C@H](CC)O)([H])O2)[C@@H](C)/C=C/[C@H](OC(C)=O)[C@](C)(O)CC1)=O | ||
分子式 | C30H48O8 | 分子量 | 536.7 |
溶解度 | DMF: Soluble,DMSO: Soluble,Ethanol: Soluble,Methanol: Soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.8632 mL | 9.3162 mL | 18.6324 mL |
5 mM | 0.3726 mL | 1.8632 mL | 3.7265 mL |
10 mM | 0.1863 mL | 0.9316 mL | 1.8632 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet